Literature DB >> 22291449

Oxidative stress promotes hypertension and albuminuria during the autoimmune disease systemic lupus erythematosus.

Keisa W Mathis1, Marcia Venegas-Pont, C Warren Masterson, Nicholas J Stewart, Katie L Wasson, Michael J Ryan.   

Abstract

Several lines of evidence suggest that essential hypertension originates from an autoimmune-mediated mechanism. One consequence of chronic immune activation is the generation of oxygen-derived free radicals, resulting in oxidative stress. Renal oxidative stress has direct prohypertensive actions on renal microvascular and tubular function. Whether oxidative stress contributes to the prevalent hypertension associated with autoimmune disease is not clear. We showed previously that female NZBWF1 mice, an established model of the autoimmune disease systemic lupus erythematosus (SLE), develop hypertension associated with renal oxidative stress. In the present study we tested the hypothesis that oxidative stress contributes to autoimmune-mediated hypertension by treating SLE and control (NZW/LacJ) mice with tempol (2.0 mmol/L) and apocynin (1.5 mmol/L) in the drinking water for 4 weeks. Although the treatment did not alter SLE disease activity (assessed by plasma double-stranded DNA autoantibodies), blood pressure and renal injury (urinary albumin) were reduced in the treated SLE mice. Tempol plus apocynin-treated SLE mice had reduced expression of nitrosylated proteins in the renal cortex, as well as reduced urinary and renal cortical hydrogen peroxide, suggesting that treatment reduced renal markers of oxidative stress. These data suggest that renal oxidative stress plays an important mechanistic role in the development of autoimmune-mediated hypertension.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22291449      PMCID: PMC3683846          DOI: 10.1161/HYPERTENSIONAHA.111.190009

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  33 in total

1.  Superoxide dismutase 1 limits renal microvascular remodeling and attenuates arteriole and blood pressure responses to angiotensin II via modulation of nitric oxide bioavailability.

Authors:  Mattias Carlström; En Yin Lai; Zufu Ma; Andreas Steege; Andreas Patzak; Ulf J Eriksson; Jon O Lundberg; Christopher S Wilcox; A Erik G Persson
Journal:  Hypertension       Date:  2010-09-27       Impact factor: 10.190

2.  T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats.

Authors:  Carmen De Miguel; Satarupa Das; Hayley Lund; David L Mattson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-02-10       Impact factor: 3.619

3.  Superoxide modulates myogenic contractions of mouse afferent arterioles.

Authors:  En Yin Lai; Anton Wellstein; William J Welch; Christopher S Wilcox
Journal:  Hypertension       Date:  2011-08-22       Impact factor: 10.190

4.  Superoxide mediates acute renal vasoconstriction produced by angiotensin II and catecholamines by a mechanism independent of nitric oxide.

Authors:  Armin Just; Andrea J M Olson; Christina L Whitten; William J Arendshorst
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-09-01       Impact factor: 4.733

5.  Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study.

Authors:  Charles J Ferro; Nicola C Edwards; Colin Hutchison; Paul Cockwell; Rick P Steeds; Caroline O Savage; Jonathan N Townend; Lorraine Harper
Journal:  Hypertens Res       Date:  2010-10-21       Impact factor: 3.872

6.  Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease.

Authors:  Carmen De Miguel; Chuanling Guo; Hayley Lund; Di Feng; David L Mattson
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-15

7.  Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis.

Authors:  Jose Herrera; Atilio Ferrebuz; Ernesto García MacGregor; Bernardo Rodriguez-Iturbe
Journal:  J Am Soc Nephrol       Date:  2006-12       Impact factor: 10.121

8.  Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus.

Authors:  E M C Sella; E I Sato; W A Leite; J A Oliveira Filho; A Barbieri
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

9.  Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus.

Authors:  Marcia Venegas-Pont; Julio C Sartori-Valinotti; Christine Maric; Lorraine C Racusen; Porter H Glover; Gerald R McLemore; Allison V Jones; Jane F Reckelhoff; Michael J Ryan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-02-04       Impact factor: 3.619

10.  Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation.

Authors:  E Waszczykowska; E Robak; A Wozniacka; J Narbutt; J D Torzecka; A Sysa-Jedrzejowska
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

View more
  41 in total

Review 1.  Sex, Oxidative Stress, and Hypertension: Insights From Animal Models.

Authors:  Jane F Reckelhoff; Damian G Romero; Licy L Yanes Cardozo
Journal:  Physiology (Bethesda)       Date:  2019-05-01

2.  Anti-CD3 antibody therapy attenuates the progression of hypertension in female mice with systemic lupus erythematosus.

Authors:  Keisa W Mathis; Erin B Taylor; Michael J Ryan
Journal:  Pharmacol Res       Date:  2017-04-08       Impact factor: 7.658

3.  Preventing autoimmunity protects against the development of hypertension and renal injury.

Authors:  Keisa W Mathis; Kedra Wallace; Elizabeth R Flynn; Christine Maric-Bilkan; Babbette LaMarca; Michael J Ryan
Journal:  Hypertension       Date:  2014-07-14       Impact factor: 10.190

4.  Expansion of regulatory T cells using low-dose interleukin-2 attenuates hypertension in an experimental model of systemic lupus erythematosus.

Authors:  Erin B Taylor; Jennifer M Sasser; Kenji J Maeda; Michael J Ryan
Journal:  Am J Physiol Renal Physiol       Date:  2019-03-20

5.  Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.

Authors:  Victoria L Wolf; Taylor L Phillips; Erin B Taylor; Jennifer M Sasser; Michael J Ryan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

6.  Urinary albumin, protein excretion and circadian blood pressure in patients with fibromyalgia.

Authors:  Baris Afsar; Rukuye Burucu
Journal:  Rheumatol Int       Date:  2013-04-16       Impact factor: 2.631

7.  Plasma Cell Depletion Attenuates Hypertension in an Experimental Model of Autoimmune Disease.

Authors:  Erin B Taylor; Michelle T Barati; David W Powell; Hannah R Turbeville; Michael J Ryan
Journal:  Hypertension       Date:  2018-01-29       Impact factor: 10.190

Review 8.  The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension.

Authors:  Steven D Crowley
Journal:  Antioxid Redox Signal       Date:  2013-04-19       Impact factor: 8.401

9.  17β-Estradiol protects against the progression of hypertension during adulthood in a mouse model of systemic lupus erythematosus.

Authors:  Emily L Gilbert; Keisa W Mathis; Michael J Ryan
Journal:  Hypertension       Date:  2013-12-23       Impact factor: 10.190

10.  Estrogen: good, bad, or both?

Authors:  Olga Rafikova; Jennifer C Sullivan
Journal:  Hypertension       Date:  2013-12-23       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.